| 14.38 Data as of May 17 |  +0.12 / +0.84%Today’s Change | 6.01 Today|||52-Week Range 15.36 | +60.13% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $517.3M |
Company Description
Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Endocyte's small molecule drug conjugates actively target receptors that are over-expressed on diseased cells, relative to healthy cells. The company is using companion imaging diagnostics that target the folate receptor and other target receptors, including prostate-specific membrane antigen, or PSMA, to guide future development of SMDCs in other oncology indications and inflammatory diseases. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.
Employees
Shareholders
| Individual stakeholders | 24.94% |
| Mutual fund holders | 22.76% |
| Other institutional | 22.44% |
Top Executives
| P. Ron Ellis, MBA | President, Chief Executive Officer & Director |
| Michael A. Sherman, MBA | Chief Financial Officer |
| Christopher P. Leamon, PhD | Vice President-Research & Development |
| Philip S. Low, PhD | Director & Chief Scientific Officer |
| Binh Nguyen, MD, PhD | Vice President-Clinical Affairs |
.
